S-aceclidine | 59653-42-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: S-aceclidine
• 英文别名: (-)-Aceclidine；(S)-Aceclidine；[(3S)-1-azabicyclo[2.2.2]octan-3-yl] acetate
• CAS: 59653-42-8
• 化学式: C₉H₁₅NO₂
• 分子量: 169.224
• InChiKey: WRJPSSPFHGNBMG-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  S-aceclidine 在 sodium hydroxide 作用下， 反应 1.0h， 生成 (S)-(+)-3-喹宁醇
  参考文献：
  名称：

  Synthesis of (R) and (S)-3-Aminoquinuclidine from 3-Quinuclidinone and (S) and (R)-1-Phenethylamine

  摘要：

  The synthesis of (R) and (S)-3-amino quinuclidine, an important building block for the synthesis of chiral 5-HT3 serotonin receptor antagonists, is described. The key reaction is the reduction by NaBH4 of the imine prepared from the 3-quinuclidinone and chiral (S) or (R)-1-phenethylamine.

  DOI：

  10.1080/00397919208021320
• 作为产物：
  描述：

  乙酰克里定 生成 S-aceclidine
  参考文献：
  名称：

  Synthesis of (R) and (S)-3-Aminoquinuclidine from 3-Quinuclidinone and (S) and (R)-1-Phenethylamine

  摘要：

  The synthesis of (R) and (S)-3-amino quinuclidine, an important building block for the synthesis of chiral 5-HT3 serotonin receptor antagonists, is described. The key reaction is the reduction by NaBH4 of the imine prepared from the 3-quinuclidinone and chiral (S) or (R)-1-phenethylamine.

  DOI：

  10.1080/00397919208021320

文献信息

• Boronic acid adducts of rhenium dioxime and technetium-99M dioxime complexes containing a biochemically active group
  申请人：BRACCO INTERNATIONAL B.V.

  公开号：EP0441491A1

  公开（公告）日：1991-08-14

  Boronic acid adducts of technetium-99m and radioactive rhenium dioxime complexes, each of which include biochemically active groups, are useful as diagnostic and therapeutic agents, respectively.

  锝-99m 的硼酸加合物和放射性二氧化铼络合物都含有生化活性基团，可分别用作诊断和治疗药物。
• SCREENING METHOD
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3627152A1

  公开（公告）日：2020-03-25

  The present invention provides a useful and efficient screening method for finding a cholinergic muscarinic M1 receptor positive allosteric modulator (M1PAM) with reduced cholinergic side effects. The present invention also provides a method for treating Alzheimer's disease and the like, a method for reducing cholinergic side effects, and the like which use M1PAM selected by the screening method and having a low α value, or the M1PAM and an acetylcholinesterase inhibitor.

  本发明提供了一种有用且高效的筛选方法，用于寻找具有降低胆碱能副作用的胆碱能毒蕈碱 M1 受体正性异位调节剂（M1PAM）。本发明还提供了一种治疗阿尔茨海默病等疾病的方法、一种减少胆碱能副作用的方法等，这些方法使用了通过筛选方法选出的具有低α值的M1PAM，或M1PAM和乙酰胆碱酯酶抑制剂。
• LAMPRECHT G., ARCH. PHARM. <APBD-AJ>, 1976, 309, NO 3, 235-239
  作者：LAMPRECHT G.

  DOI：——

  日期：——
• Ehlert, Frederick J.; Griffin, Michael T.; Glidden, Paul F., Journal of Pharmacology and Experimental Therapeutics, <hi>1996</hi>, vol. 279, # 3, p. 1335 - 1344
  作者：Ehlert, Frederick J.、Griffin, Michael T.、Glidden, Paul F.

  DOI：——

  日期：——
• US5387409A
  申请人：——

  公开号：US5387409A

  公开（公告）日：1995-02-07